YOLFTbeta
Assure Tech Hangzhou Co Ltd

Assure Tech Hangzhou Co Ltd

688075 · SHG · Healthcare / Biotechnology

27.62CNY-0.43 (-1.53%)

Price History

Full chart

Market Stats

Previous Close28.05
Open28.05
Day Range27.55 – 28.27
52-Week Range26.88 – 43.81
Volume367.26K
Market Cap3.93B
P/E (TTM)0.00
Forward P/E0.00
EPS0.00
Dividend Yield2.58%
Beta0.59
50-Day Avg29.24
200-Day Avg34.70

About

Assure Tech (Hangzhou) Co., Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents, and instruments in China and internationally. The company is involved in POCT and plastic product manufacturing; online sales; pharmaceutical manufacturing and sales; and medical testing. It also offers drug of abuse, infectious disease, fertility, cardiac marker, tumor marker, allergen, and veterinary tests, as well as Biochemistry, chronic disease monitoring systems, and reader and analyzers. In addition, the company offers infectious disease, fertility, fecal occult blood, and vaginal pH tests. Assure Tech (Hangzhou) Co., Ltd. was founded in 2008 and is based in Hangzhou, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Shisheng Ling
  • Employees573
  • HeadquartersBuilding 4, Hangzhou, China, 310011, China
  • Websitehttps://www.diareagent.com

Leadership

  • Mr. Shisheng LingChairman of the Board & GM · b. 1972
  • Ms. Xueying JiangVice Chairman & Deputy GM · b. 1974
  • Mr. Wen Kun DongDeputy GM & Director · b. 1983
  • Mr. Jun HanBoard Secretary · b. 1980
  • Ms. Xiao LinChief Financial Officer & Accounting Supervisor · b. 1985

Financials

Income Statement

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue111.00M163.73M209.80M1.20B1.59B6.17B503.36M540.70M453.58M
Growth (%)-+47.51%+28.14%+471.86%+32.47%+287.97%-91.84%+7.42%-16.11%
Cost of Revenue53.99M82.46M103.66M291.52M560.35M2.05B299.59M337.05M259.45M
Gross Profit57.01M81.28M106.14M908.24M1.03B4.12B203.76M203.65M453.58M
Gross Margin51.36%49.64%50.59%75.70%64.74%66.76%40.48%37.66%100.00%
Operating Expense60.44M40.22M43.84M146.42M163.86M587.24M36.28M-3.94M384.52M
Operating Income-3.43M41.06M62.30M761.82M865.07M3.53B167.48M207.58M69.06M
Operating Margin-3.09%25.08%29.70%63.50%54.43%57.23%33.27%38.39%15.22%
EBITDA-787.75K44.78M66.57M766.02M875.92M3.56B201.99M260.09M123.39M
EBITDA Margin-0.71%27.35%31.73%63.85%55.11%57.71%40.13%48.10%27.20%
Net Income-5.86M33.37M54.47M648.99M738.53M3.04B141.55M192.30M73.38M
Net Income Margin-5.28%20.38%25.96%54.09%46.47%49.38%28.12%35.56%16.18%
R&D7.87M12.15M16.19M58.45M70.38M329.07M105.27M101.08M78.65M
R&D as % of Total Revenue7.09%7.42%7.72%4.87%4.43%5.34%20.91%18.69%17.34%
Interest Expense464.59K516.50K672.00K347.30K551.42K2.03M1.67M1.18M275.57K
Interest Expense % of Total Revenue0.42%0.32%0.32%0.03%0.03%0.03%0.33%0.22%0.06%

Balance Sheet

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets159.54M187.21M218.11M1.10B3.28B6.94B5.79B5.77B5.68B
Total Liabilities95.99M84.53M55.75M289.22M673.95M1.52B683.83M569.52M515.98M
Total Equity63.36M102.53M162.36M811.69M2.61B5.42B5.11B5.20B5.16B
Cash63.20M52.68M65.25M613.34M2.05B2.14B337.36M467.92M568.27M
Total Debt11.00M4.13M10.71K15.41M4.64M46.53M15.58M4.63M-
Net Debt-52.20M-48.55M-65.24M-597.94M-2.04B-2.09B-321.77M-463.30M-

Cash Flow

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow16.51M12.19M19.44M602.20M675.94M3.74B-623.08M75.09M-9.41M
Investing Cash Flow-6.22M-19.86M-9.26M-37.77M-297.93M-3.61B-778.80M166.83M-
Financing Cash Flow21.61M-6.55M1.27M-6.11M1.06B-253.30M-459.04M-109.73M-
Capital Expenditure6.71M18.44M9.26M40.08M199.64M626.58M336.77M107.11M95.59M
Free Cash Flow9.80M-6.26M10.18M562.12M476.30M3.12B-959.85M-32.02M-105.00M
Dividends Paid386.08K317.98K129.55K--237.97M455.06M101.70M101.67M
FCF to OCF59.38%-51.33%52.36%93.34%70.47%83.26%154.05%-42.64%1116.15%
Dividend Paid to FCF3.94%-5.08%1.27%--7.64%-47.41%-317.61%-96.83%

Earnings

Report DateMar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023
EPS Estimate-----
EPS Actual21.101.542.00-0.690.40
Surprise-----
Timing-----

Key Statistics & Ratios

Market Cap3.93B
Enterprise Value2.43B
Trailing P/E0.00
Forward P/E0.00
Price / Sales9.59
Price / Book0.77
EPS0.00
Book Value39.73
Revenue (TTM)410.36M
Gross Profit (TTM)176.18M
EBITDA12.36M
Profit Margin-0.13%
Operating Margin-1.11%
Return on Equity-0.01%
Return on Assets-0.34%
Shares Outstanding127.08M
Shares Float32.30M
Beta0.59
Dividend Yield2.58%
Dividend Rate0.80
Payout Ratio400.00%

Dividends

20261×
0.80Jul 9, 2026
20251×
0.80Jul 18, 2025
20242×
0.40Nov 11, 20240.40Jul 9, 2024
20231×
5.00Jun 29, 2023
20221×
2.77Jul 5, 2022

Stock Splits

  • Jun 29, 20231.4:1
  • Jul 5, 20221.48:1